Refer A Patient

Request An Appointment

Neurology

BRIUMVI

BRIUMVI (ublituximab) is a monoclonal antibody that binds to a molecule (CD20) on the surface of immune cells called B cells.
Infusion or injection therapy referral
What it treats Relapsing forms of Multiple Sclerosis (MS)
Prescribed by Neurologists
How it’s administered Intravenous (IV) infusion
Frequency Second infusion two weeks after first infusion, third infusion 24 weeks after first infusion & subsequent infusions every 24 weeks
Length of treatment First infusion about four hours, subsequent infusions about one hour

About This Therapy

BRIUMVI (ublituximab) is a monoclonal antibody that binds to a molecule (CD20) on the surface of immune cells called B cells and removes them from circulating blood. BRIUMVI is approved by the FDA for the treatment of relapsing forms of multiple sclerosis in adults, which include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.

For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.

BRIUMVI REFERRAL FORM

BRIUMVI REFERRAL FORM

Speak with your healthcare provider to learn if this therapy is right for you, then complete the referral form below.
REFERRAL FORM →

Ready to refer a patient for BRIUMVI

Our team handles benefits verification, prior authorization, and scheduling so you can focus on care.